Impact of CYP genetic polymorphism on clinical events after percutaneous coronary intervention (PCI) for chronic total occlusion (CTO) : An ancillary study of the Japanese CTO PCI Expert Registry

Impact of CYP genetic polymorphism on clinical events after percutaneous coronary intervention (PCI) for chronic total occlusion (CTO) : An ancillary study of the Japanese CTO PCI Expert Registry - CYP genetic polymorphism and clinical events in the Japanese CTO PCI Expert Registry

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000014914

Enrollment

1000

Registered

2014-08-21

Start date

2014-08-22

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic total occlusion

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1.Patients enrolled in the Japanese CTO PCI Expert Registry from July 2013 to June 2015 who are able to be followed up for five years 2.Patients after successful stent implantation without complications 3.Patients taking clopidogrel 4.Patients who give written informed consent for the analysis of CYP2C19 genetic polymorphism 5.Patients who are able to undergo follow-up coronary angiography or multislice computed tomography after one year

Exclusion criteria

Exclusion criteria: Patients who are ineligible for the Japanese CTO PCI Expert Registry

Design outcomes

Primary

Measure	Time frame
Major adverse cardiocerebral events (MACCE) and reocclusion during the first year	—

Countries

Japan

Contacts

Public ContactKeiko Oka

Public interest incorporated foundation Ohara HealthCare Foundation Kurashiki Clinical Research Institute

cto.e.registry@gmail.com086-486-3317

Outcome results